FHTX - Foghorn Therapeutics Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Foghorn Therapeutics (FHTX) is developing chromatin-based therapies, leveraging precise component delivery and a network of external research centers to protect profits. The EV/EBITDA market trend, which stands at 1.24, visualizes these processes. Foghorn Therapeutics (FHTX) is also expanding its portfolio of treatments against genetic tumor mutations, although cash flow volatility persists due to strict FDA oversight and dependence on major partners.

FHTX Foghorn Therapeutics, Inc.: Company Value to EBITDA in the range 11/23/2025 - 11/12/2026

foghorntx.com - analytical breakdowns and key metrics (FHTX)

- current price and projected stock value:

Stock Price Foghorn Therapeutics Inc.|FHTX - Price Target Chart

- market capitalization statistics:

Market Value Foghorn Therapeutics Inc.|FHTX - Total Company Value

- book value of equity indicators:

Net Assets per Single Share Foghorn Therapeutics|FHTX - Total Stockholders' Equity|Market Value to Book Value Ratio foghorntx.com|FHTX - Company Assets

- business debt structure and liquidity details:

- business earnings and investment ratios data:

FHTX - Final Profit|Expected Profit Foghorn Therapeutics|FHTX - Market Cap to Earnings|Future Price to Earnings Foghorn Therapeutics Inc.|FHTX - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Foghorn Therapeutics Inc.|FHTX - Operating profit before amortization|Net earnings per share for the last 12 months Foghorn Therapeutics|FHTX - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months foghorntx.com|FHTX - Net earnings per one share growth for the current year|Earnings growth forecast for next year Foghorn Therapeutics

Fundamental valuation:FHTX (Foghorn)

EV/EBITDA compares the total enterprise value, including debt, with operating profit before interest, taxes, depreciation, and amortization. Investors utilize this ratio to determine overpayment for assets with high leverage. The EV/EBITDA multiple dynamics for Foghorn Therapeutics (FHTX) allow for an assessment of capitalization resilience against external financial shocks. The transparency of clinical data and the leadership experience of Foghorn Therapeutics (FHTX) in Big Pharma partnerships mitigate the risks reflected in this metric.

Competitor analysis

EV/EBITDA Multiple TGTX (TG Therapeutics Corp)|Arcellx Therapeutics - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IRON - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SNDX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Kura Oncology (KURA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA ADC Therapeutics S.A. (ADCT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Vor Bio|Company Value to EBITDA Nkarta Corp NKTX|EV/EBITDA Multiple COEP|actiniumpharma.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ESLA (Estrella Immunopharma, Inc.)|CASI (CASI Pharmaceuticals Inc.) - Company Value to Operating Income Before Depreciation Ratio|MRKR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA IN8bio Inc|ERNA: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple gtbiopharma.com GTBP|APTO (Aptose Biosciences Inc) - EV/EBITDA Multiple|BPTH: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MEI Pharma Corp (MEIP)|VINC - Company Value to EBITDA